| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC2630 | Iap-in-1 | Novel antagonist of IAP (inhibitor of apoptosis protein) |
|
| DCC2631 | Iaxo-101 | Novel inhibitor of the cluster of differentiation 14 innate immunity pathway |
|
| DCC2632 | Ibe-667 | Novel activator of LFA-1-ICAM-1 binding |
|
| DCC2633 | Ibl-302 | First-in-class triple-acting PIM/PI3K/mTOR inhibitor, demonstrating single-agent, anti-tumour efficacy in suppression of pAKT, pmTOR and pBAD in the SKBR-3, BT-474 and HCC-1954 HER2+/PIK3CA-mutated cell lines |
|
| DCC2634 | Ibpr001 Hydrochloride | Novel Aurora kinase inhibitor |
|
| DCC2635 | Ibpr002 | Novel Aurora kinase inhibitor, revealing mechanisms of HURP in nucleation of centrosomal and kinetochore microtubules |
|
| DCC2636 | Ibrutinib-bfl | Novel fluorescent irreversible inhibitor of Bruton's tyrosine kinase (BTK) |
|
| DCC2637 | Ibs399024 | Novel HDAC6-selective inhibitor |
|
| DCC2638 | Ic2418 | MmpL3 inhibitor, being active against drug-resistant Mycobacterium tuberculosis |
|
| DCC2639 | ica-27243 | Neuronal Kv7 potassium channel activator |
|
| DCC2640 | Icagen-4 | Inhibitor of voltage-gated K(+) (Kv) channels Kv1.3 and Kv1.5 |
|
| DCC2641 | Ical-36 | Novel inhibitor of CALP, exhibiting affinity of 22.6 ± 8.0 μM for CALP and no interaction with the NHERF PDZ domains |
|
| DCC2642 | icec0943 | Novel selective inhibitor of CDK7 |
|
| DCC2643 | Ici-185282 | Potent thromboxane receptor antagonist |
|
| DCC2644 | Ici-56780 | Antimalarial agent, displaying blood schizonticidal activity against P.berghei |
|
| DCC2645 | Iclaprim | Novel selective bacterial dihydrofolate inhibitor, antibiotic, actively against Gram positive organisms |
|
| DCC2646 | Icl-ccic-0019 | Novel potent and selective inhibitor of choline kinase alpha (CHKA) |
|
| DCC2647 | Icl-sirt078 | Novel highly selective, substrate-competitive SIRT2 inhibitor, displaying a significant neuroprotective effect in a lactacystin-induced model of Parkinsonian neuronal cell death in the N27 cell line |
|
| DCC2648 | Icpd62 | Novel inhibitor of heat shock protein 90 (Hsp90), demonstrating anticancer activity against colorectal, osteosarcoma and cervical cancer cell lines |
|
| DCC2649 | Icrf-193 | DNA topoisomerase II inhibitor |
|
| DCC2650 | Ict2700 | Potent cytotoxin selectively by CYP1A1 as a tumor-selective treatment for human bladder cancers |
|
| DCC2651 | Id110460001 | Novel μ,δ-Opioid Receptor Dual-Biased Agonist, Overcoming the Limitation of Prior Biased Agonist |
|
| DCC2652 | Id110460002 | Novel μ,δ-Opioid Receptor Dual-Biased Agonist, Overcoming the Limitation of Prior Biased Agonist |
|
| DCC2653 | Id110460003 | Novel μ,δ-Opioid Receptor Dual-Biased Agonist, Overcoming the Limitation of Prior Biased Agonist |
|
| DCC2654 | idaverine | M1 and M2 Antagonist |
|
| DCC2655 | Ide-in-37 Tfa Salt | Novel highly potent substrate-selective inhibitor of insulin-degrading enzyme (IDE), blocking insulin binding while allowing glucagon cleavage, even at saturating inhibitor concentrations |
|
| DCC2656 | Ide-in-63 Tfa Salt | Novel highly potent substrate-selective inhibitor of insulin-degrading enzyme (IDE), blocking insulin binding while allowing glucagon cleavage, even at saturating inhibitor concentrations |
|
| DCC2657 | Idh2 Inhibitor | Novel isocitrate dehydrogenase 2 (IDH2) mutants inhibitor for the treatment of cancer |
|
| DCC2658 | Idi-3783 | Novel mutant-selective Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitor |
|
| DCC2659 | Ido1/2 Inhibitor 4t | The first inhibitor targeting both IDO1/2 that has excellent in vitro inhibitory activity (IDO1 IC50 = 28 nM and IDO2 IC50 = 144 nM) |
|
